ZYME · XBRL financial data

Zymeworks financial statements, every fiscal year

The same tables from 4 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ZYME's year ends in late December)

In thousands of dollars	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	412,482	76,012	76,304	105,965
Research and development	208,596	143,619	—	—
General and administrative	73,358	70,446	61,506	61,514
Other operating income (expense)	4,706	18,811	20,499	12,795
Operating income (loss)	130,528	(138,053)	(137,110)	(92,549)
Other income (expense)	(42)	291	(218)	51
Income tax expense (benefit)	10,893	(568)	6,084	1,376
Net income (loss)	124,341	(118,674)	(122,695)	(81,130)
Earnings per share, basic USD per share	1.91	(1.72)	(1.62)	(1.08)
Earnings per share, diluted USD per share	1.90	(1.72)	(1.62)	(1.08)
Weighted average shares, basic thousands of shares	65,195	68,863	75,847	75,405
Weighted average shares, diluted thousands of shares	65,249	68,863	75,879	75,413

Fiscal years (ZYME's year ends in late December)

In thousands of dollars	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	400,912	157,557	66,103	41,157
Short-term investments	91,320	216,770	—	—
Accounts receivable	33,400	19,477	55,815	4,638
Prepaid and other current assets	19,074	19,122	18,860	15,332
Total current assets	544,706	412,926	300,451	248,767
Property and equipment, net	24,713	19,847	17,650	15,502
Right-of-use asset	22,937	17,696	16,666	15,724
Goodwill	12,016	12,016	12,016	12,016
Total assets	648,725	580,880	463,091	346,527
Total current liabilities	95,625	55,763	88,294	42,318
Lease liability, non-current	24,667	22,369	15,738	14,796
Total liabilities	155,769	116,074	124,323	78,026
Accumulated deficit	(558,763)	(677,437)	(830,335)	(953,160)
Total stockholders' equity	492,956	464,806	338,768	268,501
Total liabilities and equity	648,725	580,880	463,091	346,527
Common shares outstanding (cover page) thousands of shares	64,041	70,568	69,577	73,750

Fiscal years (ZYME's year ends in late December)

In thousands of dollars	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	124,341	(118,674)	(122,695)	(81,130)
Stock-based compensation	4,015	8,102	17,792	28,034
Net cash from operating activities	144,109	(118,303)	(110,044)	(33,005)
Purchases of property and equipment	8,150	2,474	1,991	1,521
Net cash from investing activities	(53,849)	(207,253)	38,756	26,663
Proceeds from issuing common stock	107,534	26,233	0	0
Share repurchases	0	0	30,051	41,695
Net cash from financing activities	108,582	81,847	(20,452)	(18,559)
Net change in cash	199,045	(243,355)	(91,454)	(24,946)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Zymeworks	179,413	4,590	(31,948)*	71.0M	5.6 quarters	Q2 FY26 10-QJun 30, 2026
Anaptysbio	133,826	27,488*	(26,640)*	29.9M	6.2 quarters	Q4 FY26 10-KTJun 30, 2026
Amphastar Pharmaceuticals	204,588	207,608	43,300*	42.7M	—	Q3 FY26 10-QSep 30, 2026
ImmunityBio	75,670	51,240	(66,494)*	1.1B	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Evoke Pharma	11,576	4,284	(522)*	1.7M	22.2 quarters	Q3 FY25 10-QSep 30, 2025
Anavex Life Sciences	118,326	not reported	(9,096)*	92.7M	13.0 quarters	Q3 FY26 10-QJun 30, 2026
Stoke Therapeutics	107,271	11,255	(62,686)*	65.4M	5.2 quarters	Q3 FY26 10-QSep 30, 2026
Trevi Therapeutics	54,302	not reported	(17,429)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Immunome	217,706	0	(61,692)*	113.6M	8.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 5:35 PM ET. The filing on SEC.gov is the record.